Ask AI
ProCE Banner Activity

Enhancing Care for Veterans With Small-Cell Lung Cancer: Integrating Immunotherapy and Emerging Therapies to Improve Outcomes

Clinical Thought

The standards of care in small-cell lung cancer (SCLC) are being reshaped by integration of immunotherapy and novel agents earlier in the disease course. How are you integrating these evidence-based strategies to improve outcomes for veterans with SCLC?

Released: November 07, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Amgen and Jazz Pharmaceuticals, Inc.

Amgen

Jazz Pharmaceuticals, Inc.

Disclosure

Primary Author

Mark A. Socinski, MD: consultant/advisor/speaker: AstraZeneca, BeiGene, Genentech, Guardant, Janssen, Jazz, Lilly, Regeneron, Spectrum, Summit; researcher (paid to institution): AstraZeneca, BeiGene, Cullinen, Enliven, Genentech.